Spirulina and interstitial lung disease: TGF-β fibrosis, alveolar NOX2, and immunosuppressant context

ILD pathophysiology

Alveolar macrophage NOX2:In idiopathic pulmonary fibrosis (IPF) and other ILDs, alveolar macrophages are persistently activated and generate NOX2-derived superoxide. This oxidative burst damages alveolar epithelial cells (AEC II), triggers apoptosis, and releases DAMPs that activate TGF-β1 signalling in adjacent fibroblasts. Phycocyanobilin’s NOX2 inhibition addresses the upstream oxidative trigger of the fibrotic cascade.
TGF-β1 fibroblast activation:TGF-β1 converts lung fibroblasts to myofibroblasts — cells that deposit collagen I and III, contract the interstitium, and reduce lung compliance. IPF’s progressive course is driven by this myofibroblast activation. NOX4 (not NOX2) is the primary intracellular ROS source in TGF-β1-driven fibroblast activation. Phycocyanobilin’s NOX2 preference means the direct fibrotic pathway is less well addressed than the upstream alveolar injury.
ILD subtypes:IPF (idiopathic, irreversible, progressive), non-specific interstitial pneumonia (NSIP, often connective tissue disease-associated), hypersensitivity pneumonitis (HP, antigen-driven), sarcoidosis, and CTD-ILD (scleroderma, RA, SLE, Sjögren’s syndrome). Management and immunosuppressant context differ significantly.

Pirfenidone is a TGF-β1 pathway inhibitor and antifibrotic used in IPF. It is metabolised by CYP1A2. Fluvoxamine (a CYP1A2 inhibitor) significantly increases pirfenidone exposure — this is a documented drug interaction. Spirulina compounds are not documented CYP1A2 inhibitors; no known pharmacokinetic interaction with pirfenidone.
Pirfenidone causes photosensitivity and GI side effects (nausea, diarrhoea). Spirulina’s GI polysaccharides may modestly worsen GI side effects in sensitive patients. Introduce spirulina carefully if pirfenidone GI tolerance is an issue.

Nintedanib is a tyrosine kinase inhibitor (FGFR, PDGFR, VEGFR) reducing fibroblast proliferation and myofibroblast differentiation. Used in IPF, scleroderma-ILD, and progressive fibrosing ILD. GI side effects (diarrhoea in 60%+) are the major tolerability issue. Spirulina polysaccharides may compound GI side effects; start very low (1 g) and titrate carefully if on nintedanib. No pharmacokinetic interaction documented.

CTD-ILD (particularly scleroderma and RA-ILD) is treated with mycophenolate mofetil, azathioprine, or rituximab. HP is treated with prednisolone +/- azathioprine. Sarcoidosis with prednisolone. The immunosuppressive context applies as in other autoimmune conditions: spirulina’s NK stimulation requires specialist discussion alongside immunosuppression.
IPF is not an autoimmune disease and is not treated with immunosuppression (corticosteroids worsen outcomes in IPF). In IPF specifically on pirfenidone or nintedanib only: the immunosuppressive concern does not apply.

ILD causes increased work of breathing and elevated REE in advanced disease. Protein malnutrition is common. Spirulina’s complete protein in a small-volume format (5 g spirulina = 3–4 g protein in a teaspoon) is practically relevant for patients with dyspnoea limiting food intake.
Iron deficiency anaemia worsens exercise tolerance and hypoxaemia in ILD. Ferritin should be checked; spirulina iron may contribute to maintenance but therapeutic correction of iron deficiency requires oral or IV iron.

IPF on pirfenidone or nintedanib: 1–2 g/day starting dose; increase slowly given GI side effects of antifibrotics; no pharmacokinetic interaction documented
CTD-ILD on immunosuppression (mycophenolate, rituximab): inform specialist before starting; NK stimulation concern applies
HP on corticosteroids: corticosteroid-driven metabolic effects (weight gain, glucose dysregulation) are where spirulina’s adiponectin and insulin sensitising effects are most relevant
Sarcoidosis: hypercalcaemia is a known complication of active sarcoidosis (1,25-OH vitamin D production by granulomas). Spirulina has low calcium content — not a specific concern. Vitamin D in spirulina is negligible.